This is an oral medication in an orally disintegrating tablet form.
Tascenso ODT® is a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.
Tascenso ODT was approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
Tascenso ODT is considered to be bioequivalent to Gilenya but is not a generic product; it is a brand name product. Tascenso ODT has the same active ingredient (fingolimod) as brand name Gilenya and as the generic fingolimod products. Tascenso ODT works in the body the same as Gilenya (fingolimod) capsules.
Click here to read the Tascenso ODT Prescribing Information for healthcare professionals.
Click here to read the Tascenso ODT Medication Guide for patients.
Financial Assistance Program